Research programme: neurodegenerative and ophthalmic disease therapeutics - Stealth BioTherapeutics
Alternative Names: SBT-550 series of compounds; SBT-550 series of compounds - Stealth BiotherapeuticsLatest Information Update: 28 Feb 2024
At a glance
- Originator Stealth BioTherapeutics
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders; Neurodegenerative disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Eye-disorders in USA
- 28 Feb 2024 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 13 May 2021 Stealth BioTherapeutics has multiple patent pending application in the US